Anticoagulation Management Services

BWH AMS Staff
- Pharmacists: Pharmacy Leadership, 9.5 Pharmacists, 4 per diem Pharmacists
- Multiple pharmacists recognized as Certified Anticoagulation Care Providers
- Program Coordinator
- Two Co-Medical Directors
- Interns: 4 Pharmacy Interns
- BWH AMS recognized as an Anticoagulation Center of Excellence by the AC Forum
- Credentialed Midlevel Practitioners working under an Anticoagulation-related Collaborative Practice Agreement

BWH AMS Manages Approximately 3,000 Patients on Anticoagulation for a Variety of Indications

- Warfarin Patients = 2800
- DOAC Patients = 32
- Self Testing Patients = 410
- Self Management Patients = 20
- Cardiac Surgery Referrals = 172
- Orthopedic Surgery Referrals = 626
- New Patient Referrals = 593

Publications, Guidelines and Events
- Monthly AMS M&M Conference led by rotating AMS Pharmacist
- Hosted the 11th Annual U.S. DawnAC UserGroup Meeting
- Updated Hospital-Wide Anticoagulation Guidelines
  - DOAC Management Plan
  - DOAC Conversions Guideline
  - DOAC Dosing Guideline
  - DOAC Drug Interactions Guideline
  - DOAC Perioperative Guideline
  - Periprocedural Anticoagulation & Bridging Guideline
Workload Metrics
- ~ 68,000 INRs Dosed
- ~ 1,000 Peri-procedural Anticoagulation Plans Created
- ~ 400 New Patient Educations
- ~ 2800 Annual Reviews
- Additional Services Include: Standing Orders, Medication Refills, and Ongoing Patient/Provider Anticoagulation Education

AMS Quality Metrics
The following metrics are evaluated for the general population and patients with Ventricular Assist Devices and are compared against national benchmarking data
- Time in Therapeutic Range
- Critical High and Low INRs
- Anticoagulation-Related Events

![BWH AMS Time in Therapeutic Range](image)

**Benchmark 66%**

![Event Rates All AMS Patients](image)

<table>
<thead>
<tr>
<th>Year</th>
<th>GI Bleed</th>
<th>ICH</th>
<th>Hematoma</th>
<th>Hematuria</th>
<th>Epistaxis</th>
<th>Hemoptysis</th>
<th>CVA</th>
<th>TIA</th>
<th>MT/Valvular Thrombus</th>
<th>Pulmonary</th>
<th>DVT</th>
<th>PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY'12</td>
<td>1.74%</td>
<td>0.01%</td>
<td>0.33%</td>
<td>0.22%</td>
<td>0.13%</td>
<td>0.22%</td>
<td>0.07%</td>
<td>0.15%</td>
<td>0.20%</td>
<td>0.12%</td>
<td>0.12%</td>
<td>0.08%</td>
</tr>
<tr>
<td>FY'13</td>
<td>1.05%</td>
<td>0.14%</td>
<td>0.37%</td>
<td>0.29%</td>
<td>0.17%</td>
<td>0.18%</td>
<td>0.25%</td>
<td>0.10%</td>
<td>0.20%</td>
<td>0.11%</td>
<td>0.09%</td>
<td>0.09%</td>
</tr>
<tr>
<td>FY'14</td>
<td>1.18%</td>
<td>0.14%</td>
<td>0.33%</td>
<td>0.29%</td>
<td>0.13%</td>
<td>0.18%</td>
<td>0.21%</td>
<td>0.10%</td>
<td>0.20%</td>
<td>0.12%</td>
<td>0.12%</td>
<td>0.08%</td>
</tr>
<tr>
<td>FY'15</td>
<td>2.75%</td>
<td>0.19%</td>
<td>0.44%</td>
<td>0.35%</td>
<td>0.35%</td>
<td>0.27%</td>
<td>0.51%</td>
<td>0.15%</td>
<td>0.25%</td>
<td>0.12%</td>
<td>0.12%</td>
<td>0.11%</td>
</tr>
<tr>
<td>FY'16</td>
<td>2.95%</td>
<td>0.16%</td>
<td>0.28%</td>
<td>0.29%</td>
<td>0.24%</td>
<td>0.10%</td>
<td>0.59%</td>
<td>0.16%</td>
<td>0.24%</td>
<td>0.11%</td>
<td>0.11%</td>
<td>0.11%</td>
</tr>
<tr>
<td>FY'17</td>
<td>2.05%</td>
<td>0.02%</td>
<td>0.22%</td>
<td>0.19%</td>
<td>0.26%</td>
<td>0.10%</td>
<td>0.47%</td>
<td>0.04%</td>
<td>0.20%</td>
<td>0.12%</td>
<td>0.12%</td>
<td>0.12%</td>
</tr>
</tbody>
</table>